Clinical Trial Update: Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing ACH-0141625 or placebo with peginterferon and ribavirin in hepatitis C patients; safety, tolerability, and antiviral activity rep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ACH-0141625

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2014-09-10